Master Your GLP-1 Clinical Trials with Certainty
Navigate your GLP-1 clinical trials with confidence. YPrime’s GLP-1 Playbook equips you with essential strategies to implement eCOA effectively, while highlighting key pitfalls to avoid to improve your clinical research.
Why You Need This Playbook
The GLP-1 market is projected to reach $157.5 billion by 2035.1 With over 300 drugs in development2 and leading medications achieving 15-22% mean weight loss,3 the pressure to optimize trial operations has never been greater.
As GLP-1 research advances, these promising areas highlight the expanding potential of this important drug class beyond weight management and diabetes treatment, including:
![The GLP-1 Revolution](https://www.yprime.com/wp-content/uploads/2025/02/The-GLP-1-Revolution.png)
YPrime has supported numerous GLP-1 clinical trials for both top global pharma leaders and emerging biotechs, delivering both eCOA and IRT. In one study, YPrime supported 10,000+ patients globally with our industry-leading eCOA platform.
Access Our New GLP-1 Playbook and Discover
If you are clinical trial sponsor or CRO working in clinical operations, study management, therapeutic excellence, or eClinical technology, download this important playbook and equip yourself to drive greater efficiency in GLP-1 clinical trials.
- Roots Analysis Business Research & Consulting, GLP-1 Market: Industry Trends and Global Forecasts. https://www.rootsanalysis.com/reports/glp-1-market.html. Accessed January 27, 2025.
- Clinical Trials Arena, 2024 was a record year for obesity trials and 2025 is already poised to take over. https://www.clinicaltrialsarena.com/analyst-comment/2024-record-year-obesity-trials-2025-poised-take-over/. Accessed January 27, 2025.
- CBS News Healthwatch, As many as 1 in 5 people won’t lose weight with GLP-1 drugs, experts say. https://www.cbsnews.com/news/1-in-5-people-wont-lose-weight-glp-1-drugs-experts/. Accessed January 27, 2025.